Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 2046Neoplasms 1460Carcinoma, Non-Small-Cell Lung 1364Prostatic Neoplasms 1106Multiple Myeloma 873Leukemia, Myeloid, Acute 772Colorectal Neoplasms 713Neoplasm Metastasis 704Lung Neoplasms 697Melanoma 688Lymphoma 666Leukemia 596Lymphoma, Non-Hodgkin 593Leukemia, Lymphocytic, Chronic, B-Cell 535Ovarian Neoplasms 535Pancreatic Neoplasms 500Precursor Cell Lymphoblastic Leukemia-Lymphoma 485Recurrence 474Myelodysplastic Syndromes 425Lymphoma, Follicular 418Carcinoma, Renal Cell 412Head and Neck Neoplasms 408Glioblastoma 380Lymphoma, Large B-Cell, Diffuse 379Brain Neoplasms 376Hodgkin Disease 354Carcinoma, Hepatocellular 333Squamous Cell Carcinoma of Head and Neck 326Lymphoma, Mantle-Cell 306Sarcoma 286

Interventions

ixabepilone 1Paclitaxel 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Solid Malignancies × Clear all
NCT00162136 2020-11-02

Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.

R-Pharm

Phase 1 Completed
35 enrolled 17 charts

Solid Malignancies

NCT02640755 2019-04-22

14C

AstraZeneca

Phase 1 Completed
4 enrolled 34 charts

Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡